BioVaxys Technology (FRA:5LB) Total Liabilities : €2.03 Mil (As of Jan. 2025)

View and export this data going back to 2020. Start your Free Trial

What is BioVaxys Technology Total Liabilities?

BioVaxys Technology's Total Liabilities for the quarter that ended in Jan. 2025 was €2.03 Mil.

BioVaxys Technology's quarterly Total Liabilities increased from Jul. 2024 (€1.79 Mil) to Oct. 2024 (€2.15 Mil) but then declined from Oct. 2024 (€2.15 Mil) to Jan. 2025 (€2.03 Mil).

BioVaxys Technology's annual Total Liabilities increased from Oct. 2022 (€1.22 Mil) to Oct. 2023 (€2.41 Mil) but then declined from Oct. 2023 (€2.41 Mil) to Oct. 2024 (€2.15 Mil).

BioVaxys Technology Total Liabilities Historical Data

The historical data trend for BioVaxys Technology's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology Total Liabilities Chart

BioVaxys Technology Annual Data

Trend

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Oct24

Total Liabilities

Get a 7-Day Free Trial

0.58

0.23

1.22

2.41

2.15

BioVaxys Technology Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
Total Liabilities	Get a 7-Day Free Trial															1.97	1.90	1.79	2.15	2.03

BioVaxys Technology Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

BioVaxys Technology's Total Liabilities for the fiscal year that ended in Oct. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2.149	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	2.15

Total Liabilities	=	Total Assets (A: Oct. 2024 )	-	Total Equity (A: Oct. 2024 )
	=	0.868	-	-1.281
	=	2.15

BioVaxys Technology's Total Liabilities for the quarter that ended in Jan. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2.03	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	2.03

Total Liabilities	=	Total Assets (Q: Jan. 2025 )	-	Total Equity (Q: Jan. 2025 )
	=	0.86	-	-1.17
	=	2.03

BioVaxys Technology Total Liabilities Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

BioVaxys Technology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (FRA:5LB) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

BVAXF:USA BIOV:Canada

Address

595 Howe Street, Suite 303, Vancouver, BC, CAN, V6C 2T5

Website

https://www.biovaxys.com

BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.

BioVaxys Technology Headlines

No Headlines